LONDON, Oct. 12, 2017 /PRNewswire/ --
Human Papillomavirus (HPV) Associated Cancer - Pipeline
Review, H2 2017
Summary
Download the full report:
https://www.reportbuyer.com/product/2511198
Global Markets Direct's latest Pharmaceutical and Healthcare
disease pipeline guide Human Papillomavirus (HPV) Associated Cancer
- Pipeline Review, H2 2017, provides an overview of the Human
Papillomavirus (HPV) Associated Cancer (Oncology) pipeline
landscape.
Human papillomavirus (HPV) is the most common viral infection of
the reproductive tract. Human papillomavirus (HPV) has been found
to be associated with several types of cancer. Risk factors include
smoking, weakened immune system, long-term oral contraceptive use
and chronic inflammation. Human papillomavirus (HPV) associated
cancer have no symptoms until it is quite advanced, very serious
and hard to treat.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest
pipeline guide Human Papillomavirus (HPV) Associated Cancer -
Pipeline Review, H2 2017, provides comprehensive information on the
therapeutics under development for Human Papillomavirus (HPV)
Associated Cancer (Oncology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press
releases.
The Human Papillomavirus (HPV) Associated Cancer (Oncology)
pipeline guide also reviews of key players involved in therapeutic
development for Human Papillomavirus (HPV) Associated Cancer and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III,
Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2,
16, 8, 39, 6 and 1 respectively. Similarly, the Universities
portfolio in Phase II, Phase I, Preclinical and Discovery stages
comprises 2, 2, 11 and 3 molecules, respectively.
Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline
guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities
and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and
information sourced from Global Markets Direct's proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real
time basis.
Note: Certain content / sections in the pipeline guide may be
removed or altered based on the availability and relevance of
data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic
landscape of Human Papillomavirus (HPV) Associated Cancer
(Oncology).
- The pipeline guide reviews pipeline therapeutics for Human
Papillomavirus (HPV) Associated Cancer (Oncology) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
- The pipeline guide covers pipeline products based on several
stages of development ranging from pre-registration till discovery
and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
- The pipeline guide reviews key companies involved in Human
Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and
enlists all their major and minor projects.
- The pipeline guide evaluates Human Papillomavirus (HPV)
Associated Cancer (Oncology) therapeutics based on mechanism of
action (MoA), drug target, route of administration (RoA) and
molecule type.
- The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
- The pipeline guide reviews latest news related to pipeline
therapeutics for Human Papillomavirus (HPV) Associated Cancer
(Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis,
and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage.
- Find and recognize significant and varied types of therapeutics
under development for Human Papillomavirus (HPV) Associated Cancer
(Oncology).
- Classify potential new clients or partners in the target
demographic.
- Develop tactical initiatives by understanding the focus areas of
leading companies.
- Plan mergers and acquisitions meritoriously by identifying key
players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by
understanding Human Papillomavirus (HPV) Associated Cancer
(Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued
projects and understand from the know-how what drove them from
pipeline.
Download the full report:
https://www.reportbuyer.com/product/2511198
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
https://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
View original
content:http://www.prnewswire.com/news-releases/human-papillomavirus-hpv-associated-cancer---pipeline-review-h2-2017-300535806.html
SOURCE ReportBuyer